NCT07539220Not yet recruiting
Establishment of Biomarker Panel For Forecasting Chronic Graft-Versus-Host Disease (cGVHD) After Allo-HSCT
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
This study is a single-center observational clinical study. Participants were enrolled as two cohorts of patients including discovery cohort and validation cohort. A total of consecutive 1000 patients receiving allo-HSCT in our center from 2021.01 to 2023.06 were retrospectively included as discovery cohort. A total of consecutive 500 recipients from 2023.06 to 2024.06 were retrospectively enrolled as validation cohort. Heparinized blood samples were collected prospectively at day +90 after HSCT and the onset of manifestations in patients with cGVHD or at matched time points in controls. Patients in the validation cohort also had samples drawn at approximately day +90. We used multiplex mass spectrometry with pooled plasma for biomarker discovery in comparing proteomic profiles between patients with and without chronic GVHD.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1500 (estimated)
- First submitted
- 13 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Oct 2028
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- NCT number
- NCT07539220
What you commit to
- Study type: Interventional
- Planned participants: 1500
- From Apr 2026 to the primary completion date, Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous autologous or allogeneic stem cell transplantation before enrollment.
Other illness
- Suffering from mental illness or other conditions and not being able to cooperate with research treatment and monitoring requirements.
- Patients with other special conditions who were assessed as unqualified by the researchers.
Who the study is looking for
- Patients with hematological disease survived more than 3 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Over 18 years old.
- Written informed consent or a waiver by the Ethics Committee (EC) at the site.
- HIV negative, HBV, HCV negative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.